Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study

Aung Pyae Phyo, Standwell Nkhoma, Kasia Stepniewska, Elizabeth A Ashley, Shalini Nair, Rose McGready, Carit ler Moo, Salma Al-Saai, Arjen M Dondorp, Khin Maung Lwin, Pratap Singhasivanon, Nicholas P J Day, Nicholas J White, Tim J C Anderson, François Nosten, Aung Pyae Phyo, Standwell Nkhoma, Kasia Stepniewska, Elizabeth A Ashley, Shalini Nair, Rose McGready, Carit ler Moo, Salma Al-Saai, Arjen M Dondorp, Khin Maung Lwin, Pratap Singhasivanon, Nicholas P J Day, Nicholas J White, Tim J C Anderson, François Nosten

Abstract

Background: Artemisinin-resistant falciparum malaria has arisen in western Cambodia. A concerted international effort is underway to contain artemisinin-resistant Plasmodium falciparum, but containment strategies are dependent on whether resistance has emerged elsewhere. We aimed to establish whether artemisinin resistance has spread or emerged on the Thailand-Myanmar (Burma) border.

Methods: In malaria clinics located along the northwestern border of Thailand, we measured six hourly parasite counts in patients with uncomplicated hyperparasitaemic falciparum malaria (≥4% infected red blood cells) who had been given various oral artesunate-containing regimens since 2001. Parasite clearance half-lives were estimated and parasites were genotyped for 93 single nucleotide polymorphisms.

Findings: 3202 patients were studied between 2001 and 2010. Parasite clearance half-lives lengthened from a geometric mean of 2·6 h (95% CI 2·5-2·7) in 2001, to 3·7 h (3·6-3·8) in 2010, compared with a mean of 5·5 h (5·2-5·9) in 119 patients in western Cambodia measured between 2007 and 2010. The proportion of slow-clearing infections (half-life ≥6·2 h) increased from 0·6% in 2001, to 20% in 2010, compared with 42% in western Cambodia between 2007 and 2010. Of 1583 infections genotyped, 148 multilocus parasite genotypes were identified, each of which infected between two and 13 patients. The proportion of variation in parasite clearance attributable to parasite genetics increased from 30% between 2001 and 2004, to 66% between 2007 and 2010.

Interpretation: Genetically determined artemisinin resistance in P falciparum emerged along the Thailand-Myanmar border at least 8 years ago and has since increased substantially. At this rate of increase, resistance will reach rates reported in western Cambodia in 2-6 years.

Funding: The Wellcome Trust and National Institutes of Health.

Copyright © 2012 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Parasite clearance half-life of Plasmodium falciparum on the Thailand–Myanmar border over 10 years We plotted untransformed parasite clearance half-lives over time for all malaria infections with a good fit to a linear model (R2>0.8). Data from western Cambodia gathered between June, 2007, and November, 2010, are shown for comparison, compressed as if they had been obtained in a single year. The dotted red line shows a threshold value of 6·2 h, used to differentiate between fast-clearing and slow-clearing infections. The dotted blue boxes show the periods for which bloodspots were available. These two time windows form the basis of the genetic analysis.
Figure 2
Figure 2
Change in parasite clearance half-life of Plasmodium falciparum 2001–10 (A) Geometric means of parasite clearance half-life in patients with hyperparasitaemia on the Thailand–Myanmar border. *Subset of infections treated with artesunate monotherapy (ART) for more than 48 h, for which 48 h clearance rates and parasite clearance half-lives were calculated. Error bars are 95% CIs and above them is the number of patients. (B) Proportion of patients with very slow clearance (parasite clearance half-life≥6·2 h). Error bars are binomial 95% CIs. Colour scheme is as per A.
Figure 3
Figure 3
Effect of parasite genotype on parasite clearance rates Clearance half-lives in patients infected with parasites bearing identical 93-locus genotypes. Red dotted line marks the 6·2 h threshold used to categorise slow-clearing parasites. The arrows show slow clearance parasite genotypes gathered in November, 2003. *Ranked by mean parasite clearance half-life.

References

    1. Noedl H, Se Y, Schaecher K. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–2620.
    1. Dondorp AM, Nosten F, Yi P. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–467.
    1. WHO . Global malaria control and elimination: report of a meeting on containment of artemisinin tolerance. World Health Organization; Geneva: 2009.
    1. Dondorp AM, Yeung S, White L. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272–280.
    1. Verdrager J. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. J Trop Med Hyg. 1986;89:277–289.
    1. Payne D. Spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today. 1987;3:241–246.
    1. White NJ. Artemisinin resistance—the clock is ticking. Lancet. 2010;376:2051–2052.
    1. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science. 2004;305:1124.
    1. Anderson TJ, Roper C. The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop. 2005;94:269–280.
    1. Maude RJ, Pontavornpinyo W, Saralamba S. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J. 2009;8:31.
    1. WHO . Global plan for artemisinin resistance containment (GPARC) World Health Organization; Geneva: 2011.
    1. Stepniewska K, Ashley E, Lee SJ. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2011;201:570–579.
    1. White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330–334.
    1. Saralamba S, Pan-Ngum W, Maude RJ. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci USA. 2011;108:397–402.
    1. Anderson TJ, Nair S, Nkhoma S. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis. 2010;201:1326–1330.
    1. Carrara VI, Zwang J, Ashley EA. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One. 2009;4:e4551.
    1. Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ. The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg. 1997;91:256–262.
    1. Luxemburger C, Nosten F, Raimond SD, Chongsuphajaisiddhi T, White NJ. Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. Am J Trop Med Hyg. 1995;53:522–525.
    1. WHO Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94(suppl 1):1–90.
    1. Visscher PM, Hill WG, Wray NR. Heritability in the genomics era—concepts and misconceptions. Nav Rev Genet. 2008;9:255–266.
    1. Flegg JA, Guerin P, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011;10:339.
    1. Bethell D, Se Y, Lon C. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One. 2011;6:e19283.
    1. Song J, Socheat D, Tan B. Randomized trials of artemisinin-piperaquine, dihydroartemisinin–piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia–Thailand border area. Malar J. 2011;10:231.
    1. Noedl H, Se Y, Sriwichai S. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:e82–e89.
    1. Na-Bangchang K, Ruengweerayut R, Mahamad P. Declining in efficacy of a three-day combination regimen of mefloquine–artesunate in a multi-drug resistance area along the Thai–Myanmar border. Malar J. 2010;9:273.
    1. Borrmann S, Sasi P, Mwai L. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One. 2011;6:e26005.
    1. Antao T, Hastings IM. Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria. Proc Biol Sci. 2011;278:1705–1712.
    1. Roper C, Pearce R, Bredenkamp B. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet. 2003;361:1174–1181.
    1. Alifrangis M, Lusingu JP, Mmbando B. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P falciparum dihydropteroate synthase gene. Am J Trop Med Hyg. 2009;80:523–527.
    1. Anderson TJ, Williams JT, Nair S. Inferred relatedness and heritability in malaria parasites. Proc Bio Sci. 2010;277:2531–2540.
    1. Nair S, Nash D, Sudimack D. Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites. Mol Biol Evol. 2007;24:562–573.
    1. Cheeseman I, Miller BA, Nair S. A major genome region underlying artemisinin resistance in malaria. Science. 2012 published online April 5.

Source: PubMed

3
Abonnere